Attachment D - Conflict Of Interest Reference Spreadsheet.xlsx

XLSX spreadsheet 46 KB Posted

Attached to
Patent Legal Services
Solicitation number
75F40122Q00001
Issued by

View the file

Other files

Show all 19

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

Attachment D

COI Reference Spreadsheet
Title of Patent Application or PatentCountry CodeCase TypeFiling DateApplication NumberPublication NumberPatent NumberIssue Date
RECOMBINANT MUMPS VIRUS VACCINE EXPRESSING GENOTYPE G FUSION AND HEMAGGLUTININ-NEURAMINIDASE PROTEINSUSPCT00/00/0000
USPCT12/12/19PCT/US2019/065926WO/2020/123777
INPCT00/00/0000
EPPCT6/14/21
Probabilistic Efficient Storage Algorithm for Time-Domain Spectrum MeasurementsUSU.S. Non-Provisional Application4/23/1916/391,135109297682/23/21
Respiratory Syncytial Virus (RSV) Glycoproteins (G) and fragments without a CCD domain as a vaccine or vaccine componentUS3715/12/20
Enhanced Chemiluminescent Enzyme-linked Immunosorbent Assay for Detection Of Antibodies Against Babesia microtiUSPCT20210181190
Regulatory T Cell EpitopesUSPCT4/3/2016/753,522
USPRV10/5/1762/568,625
CAPCT10/5/183077084
RF MAGNETIC FIELD HOMOGENEITY AND MAGNETIC RESONANCE IMAGE UNIFORMITY
USING INDUCTIVE COUPLINGUSCON8/25/2117/411,610
Synergistic Antitumor Activity of Combination Immunotherapy of IL-4 receptor targeted agents (e.g., IL4-PE) and^Interferons alpha and gamma in a mouse model of human ovarian cancerPCTPCT9/7/18PCT/US2018/049919WO2019/051204
A portable, low cost detection instrument for evaluation of excessive electromagnetic emissions from millimeter wave and microwave security systems used in airports to scan passengers and personnelUSU.S. Non-Provisional Application3/9/1916/295,622
USU.S. Non-Provisional Application7/10/1816/031,353102678374/23/19
USPRV7/10/1762/530,456
A novel algorithm for biological sample classifier discovery and non-supervised clustering in high-dimensional, multivariate measurement data sets using the grand canonical Monte Carlo ensemble simulation technique.US37100/00/0000
Vaccines derived from Neisseria meningitidis single, double and triple deletion mutantsUS3711/17/2016/632,278
USPRV7/21/1762/535,627
PCTPCT7/20/18PCT/US2018/043054
INPCT1/21/202.02017E11
EPPCT1/15/2018752341
BRPCT1/21/20BR11202200012556
Neisseria factor H binding protein-cholera toxin A2-choleratoxin B chimeric subunit vaccine constructs for prevention of invasive meningococcal diseaseUSCON00/00/0000
US3716/15/2016/954,161
PCTPCT12/18/18PCT/US2018/066272
Peptide Fragments From Filoviruses and Their UsesUSCON4/26/19
US3714/26/1916/346,009
PCTPCT10/31/17PCT/US2017/059407
MULTIPLEXED LATERAL FLOW ASSAYUSU.S. Non-Provisional Application2/11/1615/041,788
PCTNew PCT2/11/16PCT/US2016/0755720170234866
High Throughput And High Capacity Solid-phase Purification Of Synthetic DNA SequencesUS37112/21/1816/312,445105385461/21/20
PCTPCT6/28/17PCT/US2017/039720WO 2018/005630
PVCP Phantoms And Their Use E-2016-003/US-02USU.S. Non-Provisional Application11/2/1562/249,80999201883/20/18
SOLID HEMOGLOBIN-POLYMER BIOPHOTONIC PHANTOMS AND THEIR USEUSU.S. Non-Provisional Application6/20/1615/187,727100247857/17/18
Portable Real Time In-situ Gamma-ray Analysis SystemUS3713/1/1815/756,667US10379234A1103792348/13/19
PCTPCT9/8/16PCT/US2016/050661WO2017044555A1
Adaptive X-ray Filter Using Spatial Exposure Time Modulation With Dynamic CollimatorsUS3712/7/1815/751,119US20180228452A1
Immunogenic Peptides That Elicit Anti-Respiratory Syncytial Virus (RSV) Neutralizing AntibodiesUSCON7/16/2016/931,291
US3719/28/1715/562,862107441938/18/20
Confocal Laser Method and Device for Measurement of Optical Properties of Toric Intraocular LensesUS3711/27/1615/545,018US20180275013103025285/28/19
GBEPO1/27/1616703888.4
FREPO1/27/1616703888.4
EPPCT1/27/1616703888.4EP3250153A1EP32501533/6/19
DEEPO1/27/1616703888.432501533/18/19
CHEPO1/27/1616703888.432501533/18/19
Vibrio Assay Methods and KitsUS1119/30/1414/503,001US20150093778106047833/31/20
A Potent Anti-influenza A Neuraminidase 1 (N1) AntibodyUS3715/31/1715/532,059100720709/11/18
Application Of High Intensity Narrow Spectrum (HINS)-Light For Inactivation Of Bacteria In Ex Vivo Stored Blood Cells And Plasma In Storage BagsUS3714/2/1815/765424
EPPCT4/30/1816784311
Identification And Isolation Of Novel Anti-bacterial Compounds From Paenibacillus Biocontrol Strains TS-15 And A6-6iUSDIV9/27/1816/145,064US2019-0016757A1
USU.S. Non-Provisional Application2/7/16US15/371683US20170145057A11011894811/6/18
JPPCT6/9/152016-572236JP2017530088A566985565/1/20
GBEPO6/9/15EP2015730627EP3152224A131522247/25/18
FREPO6/9/15EP2015730627EP3152224A131522247/25/18
EPEPO6/9/15EP2015730627EP3152224A1EP31522247/25/18
DEEPO6/9/15EP2015730627EP3152224A16.02015E117/25/18
CHEPO6/9/15EP2015730627EP3152224A131522247/25/18
CAPCT6/9/15CA2951386CA2951386A1295138610/27/20
AUPCT9/6/152015274889AU2015274889A1AU20152748891/17/19
Novel Trans-acting DNA Elements For Intracellular Delivery Of Uncharged And Negatively Charged Nucleic Acid SequencesUS3719/14/1615/265,4361008746510/2/18
NIC-NANOCERIA FOR TREATMENT OF PARKINSON'S DISEASEUS37112/9/1615/317,743101829941/22/19
JPPCT12/9/162016-57254665023933/29/19
INPCT1/6/172.01747E11201747000591 A
GBPCT1/3/1715784181.831545304/18/18
FRPCT1/3/1715784181.831545304/18/18
EPPCT1/3/1715784181.83154530
DEPCT1/3/1715784181.8315453060 2015 009 678.94/18/18
Recombinant G Proteins As Vaccines Against Respiratory Syncytial Virus (RSV)USU.S. Non-Provisional Application6/1/1615/100,914103777988/13/19
INFOR7/1/162.01647E11
GBEPO7/1/1614821000.8EP30769991/22/20
FREPO7/1/1614821000.830769991/22/20
EPDIV12/2/1919206772.6
EPEPO7/1/1614821000.8EP30679912/3/34
DEEPO7/1/1614821000.8Ep30769992/22/20
CHEPO7/1/1614821000.8EP30769991/22/20
Use of Cysteamine and Deriviatives Thereof to Suppress Tumor MetastasesUSCON10/27/1916/594,827
MXPCT4/19/13MX/a/2013/004423
KRPCT4/19/1310-2013-43713
Portable Handheld Image System With Light Emitting Diodes (LED) And Colorimeter Interfaced With A Computer TableUS3716/5/1514/650,244US-2015-0310454 A1100079206/26/18
GBEPO6/11/1513859839.6EP29293183/20/19
FREPO6/11/1513859839.6EP29293183/20/19
EPEPO12/6/1313859839.6EP2929318EP29293183/20/19
DEEPO6/11/1513859839.6EP29293183/20/19
CHEPO6/11/1513859839.6EP29293183/20/19
Anti-Microbial Activity Of Synthetic PeptidesUS3712/12/1514/421,428US-2015-0322113-A192430361/26/16
PCTPCT8/15/12PCT/US2012/050969
CAFOR8/15/122882348
AUPCT2/13/15201238769620123876961/3/18
Text Mining Algorithm For Classification Of Adverse Events Reported To A Spontaneous Reporting System For Medical Product SafetyUS11912/14/1213/715,1869075796
Multifunctional Oral Vaccine Based On Chromosome RecombineeringUS3713/17/1514/428,870US-2015-023859197507939/5/17
KRPCT4/17/1510-2015-7010066
JPPCT3/17/152015-5321252015-53349162038569/19/17
INPCT2/27/15516/KOLNP/2015
HKEPO12/30/1515112845.51211980A
CNPCT5/14/152.0138E11CN 104812890 A
Hepatitis C Virus Neutralizing Epitopes, Antibodies, And MethodsUS3714/22/1514/437,59397519319/5/17
Noncontact And Self-Calibrated Dual-Confocal Laser Caliper Method For Thickness And Refractive-Index Measurement Of Intraocular Lens ImplantsUSDIV6/26/2016/913,803
US1192/26/1815/904,916107125457/14/20
MULTIVALENT MENINGOCOCCAL CONJUGATES AND METHODS FOR PREPARING CONJUGATESUSDIV8/1/1615/225,102US-2016-0331824-A99562785/1/18
US37111/21/1414/402,988US-2015-011082994274768/30/16
INPCT5/23/139791/DELNP/2014
CNPCT1/13/152.0138E11104428008
Live, Attenuated Rubella Vector To Express Vaccine AntigensUS3719/23/1414/387,514US-2015-007912395663292/14/17
Hepatitis C Virus Neutralizing AntibodyUS37111/17/1414/401,648US 2015-011824293996727/26/16
Identification Of Two Novel Biomarkers For Niemann-Pick Disease Type CEPPCT12/14/1212857972.92776588
Use Of CpG Oligonucleotides Co-formulated With an Antibiotic To Accelerate Wound HealingUS37110/24/1414/397,156US-2015-0104482 A1100765359/18/18
CAPCT3/29/132871490
AUPCT10/13/14201325278520132527853/29/13
Detection of Bacterial Contamination In A SampleUS11911/30/1213/691,511US-2013-0137119-A191037888/11/15
Direct Impact Corona Ionization (DII) Mass SpectrometryUSU.S. Non-Provisional Application10/11/1113/271,182US-2013-0087700-A187041694/22/14
US11100/00/0000
Conjugating AminesUS3719/8/1414/128,95896161394/11/17
INPCT1/8/14168/DELNP/2014
SALMONELLA TYPHI TY21A EXPRESSING YERSINIA PESTIS F1-V FUSION PROTEIN AND USES THEREOFUS37111/20/1414/402,457US-2015-015214494099568/9/16
JPPCT11/20/142015-5141552015-51906162163719/29/17
INPCT5/22/139618/DELNP/201431/2015
ILPCT11/10/14235615
CNPCT1/16/152.0138E111044705372.0138E114/26/17
FLOW CYTOMETRY-BASED SYSTEMS AND METHODS FOR DETECTING MICROBESUS3715/26/1113/059,224919486811/24/15
PAENIBACILLUS ALVEI Strain TS-15 and its Use in Controlling Pathogenic Organisms on CropsUS37111/20/1314/085,508US-2014-032216899202963/20/18
MXPCT5/18/12MX/a/2013/0135093569596/21/18
2'-O-Aminooxymethyl Nucleoside Derivatives for Use in the Synthesis and Modification of Nucleosides, Nucleotides, and OligonucleotidesUS3719/30/1314/008,805US-2014-0051846-A192843433/15/16
ITEPO10/4/1312712204.226945245.02016E145/18/16
GBEPO10/4/1312712204.2269452426945245/18/16
FREPO10/4/1312712204.2269452426945245/18/16
ESEPO10/4/1312712204.2269452426945245/18/16
EPPCT10/4/1312712204.2269452429645245/18/16
DEEPO10/4/1312712204.2269452460 2012 018 538.45/18/16
Filovirus Fusion Proteins and Their UsesUS3714/26/1313/882,041US 2013/0323243 A193479515/24/16
GBFOR10/28/1111852206.926324842/28/19
FRFOR10/28/1111852206.9263248426324842/28/18
EPEPO10/28/1111852206.9263248426324842/28/18
DEFOR10/28/1111852206.926324846.02011E112/28/18
CNPCT10/28/112.0118E11103596587 AZL201180063188.99/7/16
Mid-Infrared Imaging of MicroarraysUSPCT5/21/1313/879,15792797703/8/16
US3715/21/1313/879,157US 2014/0148352US 9,279,7703/8/16
Nanoparticle Probes And Mid-Infrared Chemical Imaging For DNA Microarray DetectionIBPCT10/14/11PCT/US2011/053248WO2012051476
Influenza Virus Recombinant ProteinsUSDIV10/19/1514/887,11598964842/20/18
US3718/14/1213/508,03017916306810/20/15
Preparation Of Conjugate Vaccine Group C Meningococcal Capsular Polysaccharidc (MCPS) To Pneumococcal Surface Adhesin A (PsaA) And Method Of Using SameUSORD4/16/0912/425,23280031128/23/11
JPPCT4/14/10201250617657448425/15/15
INPCT4/14/108274/CHENP/20113128555/17/19
CAPCT4/14/102758921275892112/4/18
Targeted Cargo Protein Combination TherapyUS11110/14/0914/812,681US-2010-018354596298994/25/17
System for Magnetic Resonance Spectroscopy of Brain Tissue for Pattern-Based DiagnosticUS3718/6/1213/509,539888035411/4/14
Deletion Of The Beta 20-21 Loop In HIV Gp120 Exposes The CD4 Binding Site For Improved Antibody Binding And Antibody InductionUSDIV11/25/1314/089,460US-2014-009352892669282/23/16
US1112/26/1012/714,085US-2010-021568286287821/14/14
Membrane Proximal Region Of HIV Gp41 Anchored To The Lipid Layer Of A Virus -like Particle VaccineUSDIV3/9/1514/642,233US-2015-0174239948651811/8/16
US3718/4/0913/057,414US-2011-014286990056314/14/15
ITEPO8/4/099805448.92324049EP23240495/25/16
GBEPO8/4/099805448.92324049EP23240495/25/16
FREPO8/4/099805448.923240495/25/16
EPPCT8/4/099805448.9232404923240495/25/16
DEEPO8/4/099805448.923240496.02009E118/24/16
CHEPO8/4/099805448.923240495/25/16
DEVICE AND METHOD FOR DETECTION OF COUNTERFEIT PHARMACEUTICALS AND/OR DRUG PACKAGINGUS3719/30/1113/262,371US 2012/0013734947683910/25/16
USCON10/24/1615/332,908US2017/00383091010128010/16/18
PCTPCT00/00/0000
GBFOR3/31/1010728465.5EP2414810
FRFOR3/31/1010728465.5EP2414810
EPFOR3/31/1010728465.5EP2414810
DEFOR3/31/1010728465.5EP2414810
CHFOR3/31/1010728465.5EP2414810
Compositions For Detecting Human Interferon-Alpha Subtypes And Methods of UseUS37111/20/0913/130,346US-2011-0311973919399511/24/15
JPDIV9/1/102015-171779P61061173/21/17
ILPCT11/20/092130102452675/29/17
AUPCT11/20/09200931641020093164101/5/17
Insertion Of Foreign Genes In Rubella Virus And Their Stable Expression In A Live, Attenuated Viral VaccineUS3714/13/1213/501,893US-2012-0207784-A1918130611/10/15
Oligonucleotides Targeting Human Endogenous Retrovirus 9 (ERV-9) Long Terminal Repeat (LTR) And Methods of UseUS3713/8/1113/062,858US-2011-016620486800653/25/14
Use Of Salmonella Enterica Serovars, Such As S. Typhi And S. Typhimurium, As Targeted Prophylactic And/or Therapeutic Delivery SystemsPCTPCT00/00/0000
CNPCT7/26/062.0061E11CN1974759B6/9/10
Neutralization of HCVUS3715/6/1012/741,612860346812/10/13
Immunogenic Peptides of Influenza VirusUS3717/12/1012/664,05287788477/15/14
Optical Techniques And System For 3-D Characterization Of Ultrasound BeamsUSORD12/21/0611/642,9892007/0204671 A1760041010/13/09
Light As A Replacement For Mitrogenic Factors On Progenitor CellsUS3719/19/0711/909,145US 2010/0055074920527612/8/15
EPEPO3/30/0617201442.53329780
EPFOR3/30/066740014.31864330186433010/19/16
CAFOR3/30/06260344326034431/8/19
AUFOR3/30/062006230329200623032910/11/12
JPFOR3/30/06JP2013096959JP2013154224
EPFOR5/2/1312159277.8247136811/15/17
Particle Image Velocimetry System Having an Improved Hollow-Waveguide-Based Laser Illumination SystemUS11110/30/0611/589,310US-2007-0115455-A177871068/31/10
Hydrophilic IR Transparent Membrane, Spectroscopic Sample Holder Comprising Same and Methods of Using SameUSDIV8/13/1213/584,208US-2012-0301917-A186528012/18/14
US1114/23/0812/150,048US-2008-0311616 A182633609/11/12
METHODS FOR PREPARING COMPLEX MULTIVALENT IMMUNOGENIC CONJUGATESZAPCT3/16/072008/079612008/079614/29/16
USDIV8/6/1313/960,6912014-0044748917503311/3/15
USDIV4/5/1213/440,856855725010/15/13
US3719/15/0812/283,894US2009-009263281731355/8/12
KRDIV3/8/1810-2018-70067221.01948E122/13/19
KRDIV2/23/1710-2017-700515110-18389383/9/18
KRDIV3/28/1610-2016-700820710-17119032/24/17
KRPCT3/16/0710-2008-702544110-14114256/18/14
INDIV3/16/072.01718E112818825/24/17
INPCT3/16/073682/KOLNP/20082818825/24/17
IDPCT3/16/07WO 0200802974IDP00003688210/1/14
GBEPO3/16/0715195219.93006041300604111/29/17
GBEPO3/16/077753268.71993604199360412/2/15
FREPO3/16/077753268.71993604199360412/2/15
EPPCT3/16/077753268.71993604199360412/2/15
DEEPO3/16/0715195219.93006041
DEEPO3/16/077753268.71993604199360412/2/15
CNPCT3/16/072.0078E11CN101405028ZL200780009505.28/19/15
CAPCT3/16/07264472426447245/24/16
BRPCT3/16/07PI0708849-32111
AUPCT3/16/07200722750420072275042/13/14
Confocal Fiber-optic Laser Method For Intraocular Lens Power MeasurementUS3715/28/0811/885,544US 2008/027871277196685/18/10
GBEPO3/3/066736741.7186407818640785/3/17
FREPO3/3/066736741.7186407818640785/3/17
EPPCT3/3/066736741.7186407818640785/2/17
DEEPO3/3/066736741.7186407818640785/3/17
CHEPO3/3/066736741.7186407818640785/3/17
Ultrahigh-Resolution Fiber-Optic Confocal Microscope and MethodUS3712/6/0911/918,313US 2009-022540984567386/4/13
EPPCT10/31/07675025018721681872168
DEEPO10/31/076750250187216812/6/17
CHEPO10/31/076750250187216812/6/17
Methods of Altering An Immune Response Induced By CpG OligonucleotidesUSDIV1/12/1113/005,488US-2011-011088384703426/25/13
JPPCT8/28/062008-5292072009-50612254810682/21/14
Use of Lymphocytes to Measure Anthrax Lethal Toxin ActivityUSDIV9/24/1012/889,955US-2012-0122116-A183833592/26/13
US3714/5/0611/399,00378035659/28/10
Compositions and Methods for the Detection of HIV-1/HIV-2 InfectionUS3715/21/1013/321,676US2012019630689805463/17/15
PCTPCT00/00/000000/00/0000
GBEPO5/21/1010721594.9243313224331322/21/18
FREPO5/21/1010721594.9243313224331322/21/18
EPEPO5/21/1010721594.9243313224331322/21/18
DEEPO5/21/1010721594.9243313224331322/21/18
Method For the Detectiion Of HIV-1 Antibodies Utlilizing a Peptide Containing a Novel GP41 EpitopeUSDIV12/23/1012/977,41191218559/1/15
USDIV12/23/1012/977,32087223245/13/14
GBEPO9/2/0510174056.1EP2295974A1230926910/26/16
GBEPO9/2/0510174062.9229597300/00/0000
GBEPO9/2/055858397.21800126180012612/17/14
FREPO9/2/0510174056.1EP2295974A1230926910/26/16
FREPO9/2/055858397.21800126180012612/17/14
EPDIV9/2/0510174056.1230926900/00/0000
EPPCT9/2/055858397.21800126180012612/17/14
DEEPO9/2/0510174056.12309269230926910/26/16
DEEPO9/2/055858397.218001266.02005E1112/17/14
CHEPO9/2/055858397.21800126180012612/17/14
Quantitative Real-Time Assay For Noroviruses And Enteroviruses With A Build-in Quality Control StandardUSCON10/1/0711/865,2282012-0129151857484411/5/13
CpG Oligonucleotides Prodrugs, Compositions Thereof And Associated Therapeutic MethodsUS1116/11/0711/721,409US2009-0263405980982411/7/17
Live, Oral Vaccine For Protection Against Shigella Dysenteria Serotype 1USDIV12/30/1414/585,721US-2015-018261094028898/2/16
USDIV12/31/1314/145,104US-2014-012013489687193/3/15
USDIV11/28/1213/687,797US-2013-0078274-A187906357/29/14
USDIV10/31/1113/285,6142012-0040433833783112/25/12
US3719/21/0711/597,301US20080193486A1807111312/6/11
LIEPO5/24/055754091.6175614917561499/4/13
ITEPO5/24/055754091.6175614917561499/4/13
IEEPO5/24/055754091.6175614917561499/4/13
GBDIV5/24/0513176694.126572513/21/18
GBEPO5/24/0512186545.5254626025462607/15/15
GBEPO5/24/055754091.6175614917561499/4/13
FRDIV5/24/0513176694.126572513/21/18
FREPO5/24/0512186545.5254626025462607/15/15
FREPO5/24/055754091.6175614917561499/4/13
EPDIV5/24/0513176694.100/00/0000
EPDIV5/24/0512186545.5254626025462607/15/15
EPPCT5/24/055754091.6175614917561499/4/13
DEDIV5/24/0513176694.126572513/21/18
DEEPO5/24/0512186545.5254626025462607/15/15
DEEPO5/24/055754091.6175614917561499/4/13
CHDIV5/24/0513176694.126572513/21/18
CHEPO5/24/0512186545.5254626025462607/15/15
CHEPO5/24/055754091.6175614917561499/4/13
BEEPO5/24/055754091.6175614917561499/4/13
CCR5-SPECIFIC ANTIBODIES WITH HIV NEUTRALIZING ACTIVITY THAT RECOGNIZE A LINEAR DODECAPEPTIDE THAT MIMICS A CONFORMATIONAL EPITOPE IN THE SECOND EXTRACELLUALAR LOOPUSDIV12/28/0912/647,789US-2010-0266598828292610/9/12
A PEPTIDE THAT ELICITS NEUTRALIZING ANTIBODIES TARGETING THE HIV CO-RECEPTOR, CCR5US11110/10/0611/578,1222008/016001077002734/20/10
Bacterial Genetic Promoters That Are Maximally Expressed Inside Host Eukaryotic Cells - Use In Vaccine DevelopmentUSDIV7/17/1213/551,1682012/028270187098134/29/14
USDIV6/8/1012/796,4102012-014909582472258/21/12
USCON3/17/0611/378,003US 2010/015096577588557/20/10
Bacterial Genetic Promoters That Are Maximally Expressed Inside Host Eukaryotic Cells - Use In Vaccine DevelopmentUSDIV6/8/1013/551,168US 2012/028270187098134/29/14
USCON6/17/1212/796,410US 2012/014909582472258/21/12
USCON9/20/0411/378,003US2010/015096577588557/20/10
EPEPO3/17/064809769.51 670 505 B111/14/12
Process for Preparing Polysaccharide-Protein Conjugate VaccinesUS3712/1/0610/566,898US-2007-0110762917393111/3/15
Polysaccharide-Protein Conjugate VaccinesZAPCT8/6/042006/016882006/168812/27/07
USCON11/2/1514/930,425US-2016-0136256947479510/25/16
USDIV5/5/1414/270,213US-2014-0322258919897612/1/15
USDIV5/10/1313/892,1632013-033700487536496/17/14
US3719/25/0610/566,899US-2007-0141084-A1804843211/1/11
USDIV8/6/0413/243,480US-2012-0076817-A184657496/18/13
LIEPO8/6/0410180008.42366404236640411/19/14
LIEPO8/6/044786467.31651261165126110/8/14
ITEPO8/6/0410180020.92366403236640310/8/14
ITEPO8/6/0410180008.42366404236640411/19/14
ITEPO8/6/044786467.31651261165126110/8/14
INDIV1/23/172.01718E11WO/2005/0140373/11/03
INDIV8/6/04832/DELNP/2010832/DELNP/20102797481/30/17
INPCT8/6/041095/DELNP/200632/20072421828/18/10
IEEPO8/6/0410180020.92366403236640310/8/14
IEEPO8/6/0410180008.42366404236640411/19/14
IEEPO8/6/044786467.31651261165126110/8/14
GBEPO8/6/0410180020.92366403236640310/8/14
GBEPO8/6/0410180008.42366404236640411/19/14
GBEPO8/6/044786467.31651261165126110/8/14
FREPO8/6/0410180020.92366403236640310/8/14
FREPO8/6/0410180008.42366404236640411/19/14
FREPO8/6/044786467.31651261165126110/8/14
EPDIV8/6/0410180020.92366403236640310/8/14
EPDIV8/6/0410180008.42366404236640411/19/14
EPPCT8/6/044786467.31651261165126110/8/14
DEEPO8/6/0410180020.92366403236640310/8/14
DEEPO8/6/0410180008.423664046.02004E1111/19/14
DEEPO8/6/044786467.316512616.02004E1110/8/14
CNPCT8/6/062.0048E112.0048E115/4/11
CNDIV8/6/042.0131E11CN 103623405ZL 201310439763.16/15/16
CNDIV8/6/042.0111E11CN1021513312.0111E1110/30/13
CHEPO8/6/0410180020.92366403236640310/8/14
CHEPO8/6/0410180008.42366404236640411/19/14
CHEPO8/6/044786467.31651261165126110/8/14
CADIV11/9/162948114CA 29481142/26/19
CADIV8/6/042844154284415412/20/16
CAPCT6/8/04253487025348705/6/14
BRDIV9/13/19BR1220190919120400/00/0000
BRDIV9/13/19BR122019019122000/00/0000
BRPCT8/6/04PI0413309-9PI0413309-9PI0413309-97/16/19
BEEPO8/6/0410180020.92366403236640310/8/14
BEEPO8/6/0410180008.42366404236640411/19/14
BEEPO8/6/044786467.31651261165126110/8/14
AUPCT8/6/04200426313520042631353/10/11
AUDIV00/00/000000/00/0000
METHOD FOR TREATING A PATIENT HAVING A SPINAL CORD INJURY USING PHOTOTHERAPYUSDIV2/25/1012/713,087US 2010-0152820832885712/11/12
USCON1/7/0811/970,425US 2008/010356276955044/13/10
USCIP12/23/0411/022,314US 2006-0036299 A173445553/18/08
INTERNAL CONTROL NUCLEIC ACID MOLECULE FOR NUCLEIC ACID AMPLIFICATION SYSTEMSUS11111/15/0511/280,474US-2006-0166232-A177281236/1/10
JPPCT5/14/042006-53307548051588/19/11
IEEPO11/28/054752246.1162523216252329/4/13
GBEPO11/28/054752246.1162523216252329/4/13
FREPO11/28/054752246.1162523216252329/4/13
EPPCT5/14/044752246.1162523216252329/4/13
DEEPO11/28/054752246.1162523216252329/4/13
CHEPO5/14/044752246.1162523216252329/4/13
Live Attenuated Leishmania VaccinesUSDIV11/15/1012/946,809887721311/4/14
US3712/28/0611/364,682US-2006-0240046-A178878122/15/11
THERMOLABILE HYDROXYL PROTECTING GROUPS AND METHODS OF USE.US37111/9/0510/556,219US-2006-0281911-A1761219711/3/09
Individualized Therapy Using Interdependent Protein Signal NetworkUSCON4/24/1213/455,11188353609/26/14
USCON10/16/0912/581,01981685685/1/12
Improved Pattern Recognition Of Whole Cell Mass Spectra Via Separation Of Specific Charge StatesUS1196/7/0410/863,74576849343/23/10
Method of Preventing Infections From Bioterrorism Agents With Immunostimulatory CPG Oligonucleotides.USDIV5/24/1012/786,326US-2010-022694184810557/9/13
US3714/29/0510/533,634US-2006-0019239-A177588767/20/10
JPDIV00/00/000000/00/0000
AUDIV00/00/000000/00/0000
METHOD OF TREATING INFLAMMATORY LUNG DISEASE WITH SUPPRESSORS OF CPG OLIGONUCLEOTIDESUSDIV7/1/1313/932,906US-2013-0281518-A190062034/14/15
USCON9/20/1113/237,831US-2012-0009170-A185011888/6/13
US11110/7/0310/682,130US-2004-0132682-A1804362210/25/11
METHOD OF TREATING INFLAMMATORY ARTHROATHIES WITH SUPPRESSORS OF CPG OLIGONUCLEOTIDESUSCON9/14/1213/619,949US-2013-0018089-A1855778910/15/13
USCON4/25/1113/093,725US-2011-0201676828835910/16/12
USCON11/28/0812/325,106US2009-014231079517865/31/11
USCON00/00/000000/00/0000
METHOD OF TREATING AND PREVENTING INFECTIONS IN IMMUNOCOMPROMISED SUBJECTS WITH IMMUNOSTIMULATORY CPG OLIGONUCLEOTIDES<CR>US1119/17/0310/666,022US-2004-0105872-A182630919/11/12
Immunostimulatory RNA/DNA Hybrid MoleculesJPFOR6/7/01JP2002501473AJP2004530629A00/00/0000
Use of CpG Oligodeoxynucleotides to Induce AngiogenesisUSCON8/15/0711/839,2172008/002702179353515/3/11
US3716/17/0410/499,597US-2005-0026245-A1761522711/10/09
USCON00/00/000000/00/0000
USDIV00/00/000000/00/0000
Methods For Predicting Properties of MoleculesUS1113/7/0310/383,602US-2003-0229456-A179961568/9/11
CHIMERIC MOLECULE FOR THE TREATMENT OF TH2-LIKE CYTOKINE MEDIATED DISORDERSUS3716/4/0410/497,80475410406/2/09
Alleviating symptoms of TH2-Like Cytokine Mediated Disorders By Reducing IL-13 receptor-Expressing Cells In The Respiratory TractAUPCT6/8/04200225801120022580114/23/09
SUPPRESSORS OF CPG OLIGONUCLEOTIDES AND METHODS OF USEUSCON9/13/1314/026,995US-2014-0134233916324410/20/15
USCON6/21/1213/530,028US-2012-0258144858094411/12/13
USDIV2/27/0912/395,53982274387/24/12
US3713/16/0410/489,83975144144/7/09
Use of Sterically Stablized Cationic Lipsomes to Efficiently Deliver CpG Oligonucleotides in VivoUS3716/4/0410/484,99176666742/23/10
Novel Method For Rapidly Generating Mature Dendritic Cells From Peripheral Blood And Myeloid ProgenitorsUSCON00/00/000000/00/0000
Vaccine For Protection Against Shigella Sonnei DiseaseUSCON3/17/1514/660,498US-2015-018261193332515/10/16
USDIV11/27/1213/686,299US 2015/018261189929433/31/15
USDIV5/28/0913/295,8112012-0058142833783212/25/12
USDIV5/28/0912/474,223US-2010-0272748807108412/6/11
US1191/15/0310/346,70675410436/2/09
High Sensitivity Mechanical Resonant BiosensorUSU.S. Non-Provisional Application11/14/0009/712,795714801712/12/06
A PROCESS FOR DISCRIMINATING BETWEEN BIOLOGICAL STATES BASED ON HIDDEN PATTERNS FROM BIOLOGICAL DATAUS1197/18/0109/906,66169253898/2/05
HEURISTIC METHOD OF CLASSIFICATIONUS1116/19/0109/883,19670962068/22/06
Thermolabile Hydroxyl Protecting Groups and Methods of UseUS3718/16/0410/497,416US-2005-0020827-A173550374/8/08
Drift Compensation Method for Fingerprint SpectraUSU.S. Non-Provisional Application10/10/0109/975,530US-2002-0138210-A169964722/7/06
Immunostimulatory Nucleic Acid MoleculesUS1117/14/03US10/619,279872237415/9/07
Oligodeoxynucleotide and Its Use to Induce an Immune ResponseUSDIV5/10/0711/801,984US-2008-0069825-A179194774/5/11
USCIP7/12/0210/194,035US-2003-0144229-A175210634/21/09
Oligodeoxynucleotide and Its Use to Induce an Immune ResponseUSCON11/9/0611/595,21116803028510/4/11
Imaging Of Drug Accumulation As A Guide for Tumor TherapyUS3713/19/0210/088,561714123411/28/06

File details come from the government source that posted it. Updated .